Collaboration Shows Vaccine Candidate Can Produce Powerful ‘Broadly Neutralizing Antibodies’ in Animal Models
Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.
“This study shows that we’re moving in the right direction for a universal flu vaccine,” said Ian Wilson, Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology at TSRI.
The study was part of TSRI’s long-term collaboration to strengthen research against infectious disease with the former Crucell Vaccine Institute, now known as Janssen Prevention Center and headquartered in Leiden, the Netherlands.
The research was published online ahead of print on August 24 by the journal Science.
The Need for Better Flu Shots
Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to the U.S. Centers for Disease Control and Prevention. While a yearly flu shot provides some protection, subtypes not covered by the vaccine can emerge rapidly. This phenomenon was evident in the 2009 spread of the H1N1 (“swine flu”) subtype that killed an estimated 151,700 to 575,400 people worldwide.
In the last decade, several studies from TSRI, Janssen and other institutions have shown that some people are capable of making powerful antibodies that can fight many subtypes of influenza at once by targeting a site on the influenza virus that does not mutate rapidly. Unfortunately, these “broadly neutralizing antibodies,” or bnAbs, are rare.
Still, the tantalizing existence of broadly neutralizing antibodies led Janssen and TRSI to try creating an influenza vaccine specially designed to elicit them.
Researchers zeroed in on a possible target: a protein on the surface of influenza, called hemagglutinin (HA). HA is present on all subtypes of influenza, providing the key viral “machinery” that enables the virus to enter cells. Most importantly, the long “stem” region of HA, which connects the virus to cells, plays such a crucial role that mutations at the site are unlikely to be passed on.
“If the body can make an immune response against the HA stem, it’s difficult for the virus to escape,” Wilson explained.
Fighting ‘Bird Flu’ and Other Strains
To create antibodies against the HA stem, the research team looked to influenza’s own structure, specifically the universal recognition site of the broadly protective antibody CR9114 in the HA stem (described by Dreyfus et al., Science 2012). This vaccine candidate was designed, produced and tested by a team of scientists led by Jaap Goudsmit, head of the Janssen Prevention Center, the paper’s first author Antonietta Impagliazzo (responsible for the design) and co-senior author Katarina Radoševi?.
The effort represents the first time scientists have been able to cut off the variable head region of HA, designing features able to stabilize the conformation of the original protein, and at the same time faithfully mimicking the key broadly neutralizing site. The ultimate goal was to use this synthetic version of the HA stem in a vaccine to teach the body to make powerful antibodies against influenza virus, priming it to fight off a variety of flu strains.
The scientists then studied the response of rodent and nonhuman primate models given one of several candidate immunogens. They found that animals given one especially stable immunogen produced antibodies that could bind with HAs in many influenza subtypes, even neutralizing H5N1 viruses (“avian” or “bird” flu).
“This was the proof of principle,” said Wilson. “These tests showed that antibodies elicited against one influenza subtype could protect against a different subtype.”
Scientists at TSRI studied the structure of the immunogen at every point in the process. Using the imaging techniques of electron microscopy (led by TSRI Associate Professor Andrew Ward and postdoctoral fellow Ryan Hoffman) and x-ray crystallography (led by Wilson and TSRI Staff Scientist Xueyong Zhu), the team showed that the most promising candidate immunogen mimicked the HA stem and that antibodies could bind with the immunogen just as they would with a real virus.
With proof that an immunogen can elicit antibodies against the stem region, Wilson said the next step in this research is to see if the immunogen can do the same in humans.
“While there is more work to be done, the ultimate goal, of course, would be to create a life-long vaccine,” Wilson said.
The Latest on: Universal flu vaccine
via Google News
The Latest on: Universal flu vaccine
- Kenya: Battle Against Flu Gets a Boost With Sh1.2 Billion Granton September 5, 2019 at 12:10 am
The world could get a universal vaccine that is effective against all strains of influenza viruses. This is after eight scientists received funding from the Bill & Melinda Gates Foundation to ...
- Battle against flu gets a boost with Sh1.2bn granton September 3, 2019 at 11:03 pm
The world could get a universal vaccine that is effective against all strains of influenza viruses. This is after eight scientists received funding from the Bill & Melinda Gates Foundation to develop ...
- Oregon hospital researching the development of a universal flu vaccineon August 30, 2019 at 2:34 pm
PORTLAND, Ore. (KWCH) - Oregon Health & Science University Hospital is researching the creation of a universal flu vaccine with the help of a grant from the Bill and Melinda Gates Foundation. The ...
- Oregon researchers aiming to make your yearly flu shot a thing of the paston August 30, 2019 at 1:48 am
Last year marked 100 years since the deadliest flu pandemic in history, known as the 1918 influenza pandemic. The centennial spurred the Bill and Melinda Gates Foundation to start the Grand Challenge ...
- Seasonal Influenza Vaccines Market Growth Rate, Manufacturers, Market Dynamics, Market Overviewon August 29, 2019 at 4:40 pm
Also, National Institute of Allergy and Infectious Disease (NIAID) is engaged in developing new strategic plan to develop novel, safe and effective universal influenza vaccine. Various government ...
- OHSU receives grant from Gates Foundation to develop universal flu vaccineon August 29, 2019 at 2:46 pm
Oregon Health & Science University received a grant from the Gates Foundation to develop the Holy Grail of vaccines: a universal flu vaccine. OHSU is one of about six institutions that are splitting ...
- Gates Foundation donates $12M to universal flu vaccine researchon August 29, 2019 at 8:59 am
Up to eight research teams will receive about $12 million in funding to research a universal flu vaccine, thanks to grants from the Bill and Melinda Gates Foundation and the philanthropic organization ...
- With new grants, Gates Foundation takes an early step toward a universal flu vaccineon August 29, 2019 at 1:46 am
Scientific teams from inside and outside the world of influenza research have been awarded funding to try to unlock mysteries that could provide the foundation for a future universal flu vaccine, the ...
- BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Resultson August 28, 2019 at 4:45 am
Recent events have positioned BiondVax to become a successful manufacturer and marketer of its M-001 universal flu vaccine candidate. In July we closed on a financing of US$20M predominantly ...
- Meet The Synthetic Biology Company Engineering Your Immune Systemon August 27, 2019 at 10:45 pm
It’s taken 30 years of biotech, but synthetic biology can now engineer antibodies in the lab faster than the body can do it, with potential cures for everything from snake bites to a universal flu ...
via Bing News